GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$161.41
+0.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 982.0M | 739.0M | 563.9M | 449.5M |
| Cost of Revenue | 413.9M | 349.0M | 289.8M | 227.1M | 156.3M |
| Gross Profit | 769.2M | 633.0M | 449.2M | 336.9M | 293.2M |
| Operating Expenses | |||||
| R&D Expense | 375.8M | 364.2M | 347.8M | 367.2M | 373.8M |
| SG&A Expense | 863.6M | 706.1M | 545.1M | 451.0M | 463.8M |
| General & Admin Expense | 233.8M | 211.4M | 180.1M | 155.8M | 164.0M |
| Selling & Marketing Expense | 629.8M | 494.7M | 364.9M | 295.2M | 299.8M |
| Other Expenses | — | — | — | 83.4M | — |
| Total Operating Expenses | 1.2B | 1.1B | 892.8M | 901.6M | 837.6M |
| Cost and Expenses | 1.7B | 1.4B | 1.2B | 1.1B | 993.9M |
| Operating Income (EBIT) | (470.3M) | (437.2M) | (443.6M) | (564.7M) | (544.4M) |
| Non-Operating | |||||
| Interest Income | 38.8M | 34.1M | 53.7M | 35.4M | 6.1M |
| Interest Expense | 4.8M | 3.9M | 2.6M | 2.6M | 2.6M |
| Net Interest Income | 34.0M | 30.2M | 51.1M | 32.8M | 3.5M |
| Other Non-Op Income/Expense | 15.8M | 19.7M | 8.5M | 86.0M | (109.1M) |
| Non-Operating Income (excl Interest) | (20.6M) | (23.6M) | (11.1M) | (88.5M) | 106.5M |
| EBT (Pre-Tax Income) | (454.5M) | (417.5M) | (435.1M) | (478.8M) | (653.4M) |
| Income Tax Expense | (1.0M) | (1.3M) | 1.3M | 685.0K | 1.1M |
| Bottom Line | |||||
| Net Income | (453.4M) | (416.3M) | (436.4M) | (479.4M) | (654.6M) |
| Earnings from Cont. Ops | (453.4M) | (416.3M) | (436.4M) | (479.4M) | (654.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (453.4M) | (416.3M) | (436.4M) | (479.4M) | (654.6M) |
| Per Share | |||||
| Basic EPS | ($3.49) | ($3.32) | ($3.56) | ($4.28) | ($6.41) |
| Diluted EPS | ($3.49) | ($3.32) | ($3.56) | ($4.28) | ($6.41) |
| Revenue Per Share | $8.96 | $7.83 | $6.02 | $5.04 | $4.40 |
| Shares | |||||
| Basic Shares Outstanding | 132.1M | 125.4M | 122.7M | 112.0M | 102.2M |
| Diluted Shares Outstanding | 132.1M | 125.4M | 122.7M | 112.0M | 102.2M |
| Profitability Metrics | |||||
| EBITDA | (411.2M) | (373.9M) | (390.1M) | (433.3M) | (614.9M) |
| D&A | 38.5M | 39.7M | 42.4M | 42.9M | 36.0M |
| EBIT | (449.7M) | (413.6M) | (432.5M) | (476.2M) | (650.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026